Chronic liver disease and impaired hepatic function are important risk factors for increased incidence of, and mortality from, acute pulmonary complications including manifest acute respiratory distress syndrome in approximately 8% of cirrhotics admitted to an intensive care unit (ICU) [1, 2]. While micro-aspiration associated with encephalopathy and hydropic decompensation are well-known triggers for pulmonary complications [3], the more specific consequences of end-stage liver disease on the pulmonary microcirculation, such as hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PoPH), result from either production of or failure to clear a broad range of inflammatory, vasoactive or proliferative/angiogenic mediators [4]. The impact of an altered bile acid pattern induces a shift in the gut microbiome [5] that sheds new light on the molecular basis of the long acknowledged ‘gut–liver–lung axis’ as the "motor of multiple organ failure".

Two discrete entities affecting the pulmonary vascular bed—hepatopulmonary syndrome and portopulmonary hypertension

In addition to these acute organ–organ interactions, prolonged stimulation by liver-derived vasoactive and proliferative mediators promotes remodeling processes in the pulmonary vascular bed in chronic liver disease through diffuse or localized telangiectasia (in HPS) or hyperplastic lesions in terminal pulmonary arterioles (in PoPH) [6].

Respiratory function needs to be assessed in all candidates listed or considered for liver transplantation (LT), as primary disorders affecting the pulmonary circulation are associated with functional status, quality of life, and survival on the waiting list and outcome after LT [7, 8].

HPS and PoPH, a form of secondary pulmonary hypertension (PAH), might also prompt unplanned admission of the patient with end-stage liver disease with dyspnea or right heart dysfunction and require immediate and appropriate care on an ICU to prevent further deterioration of an already limited liver function.

Hepatopulmonary syndrome is characterized by hypoxemia with an abnormal alveolar–arterial O₂ gradient and evidence of intrapulmonary shunting in the presence of liver disease [6, 9]. Abnormal oxygenation is defined by elevated alveolar–arterial oxygen gradient (>15 mmHg or >20 mmHg in patients >64 years, respectively) while breathing room air in a sitting position, and severity of HPS is classified according to the degree of hypoxemia [6]. The underlying intrapulmonary vascular dilatations can best be diagnosed by contrast-enhanced echocardiography, and characteristic findings on CT imaging may also be seen. In severe cases, clinical characteristics of hypoxemia such as cyanosis and digital clubbing might be present. The severity of HPS might be aggravated by upright posture (platypnea–orthodeoxia) and is not related to the severity of liver disease. In general, the pulmonary circulation is diffusely affected by telangiectatic lesions, but anatomically defined shunts might less commonly exist that are potentially amenable to interventional therapy (Fig. 1) [6].

Hepatopulmonary syndrome is present in 10–30% of patients with cirrhosis being evaluated for LT, but has also been reported in non-cirrhotic portal hypertension and acute liver injury in the critically ill, e.g., in patients after shock events presenting signs of “hypoxic hepatitis” [9]. As such, acute HPS as a consequence of acute and chronic heart failure, in particular failure of the right ventricle with hepatic congestion, can complicate the ICU course through induction of pulmonary shunting (i.e., HPS). This bi-directional cross talk of lung and liver can be viewed as a prominent example of organ–organ interactions that pave the way to multiple organ failure and death.
Supportive therapies with supplemental oxygen and liver transplantation remain the only therapies with proven benefit in cases of HPS associated with end-stage liver disease, and Model of End-Stage Liver Disease (MELD) exception can be granted to facilitate liver transplantation in various programs to reverse two potentially fatal organ dysfunctions [7, 10, 11]. Patients with HPS are at increased risk for prolonged mechanical ventilation with a longer ICU length of stay compared to other liver transplant recipients [12]. Most literature reports addressing management of these critical events reflect case reports or small case series, where inhaled vasodilators, most notably nitric oxide and extracorporeal membrane oxygenation (ECMO), have been applied as rescue strategies [13, 14]. Albeit inhaled NO might selectively dilate well-aerated alveoli, the use of vasodilators in HPS in general remains controversial and should be restricted to short-acting NO in exceptional cases and as compassionate use.

Impaired clearance of vasoactive mediators by the failing liver plays a significant role in the pathogenesis of HPS, and the resulting right-to-left shunting, mismatch between ventilation and perfusion and impaired arterial oxygenation are generally reversible with recovery of hepatic function [7, 8, 10]. As a consequence, persistent severe hypoxemia and features of HPS despite improved liver function might reflect and should prompt search for concomitant anatomic shunting. However, in severe cases of HPS, remodeling of the pulmonary vasculature and reversal of shunting due to diffuse telangiectasia may take weeks or months. Pre-transplant risk assessment and classification of severity of HPS is mandatory, as
patients with a \( \text{paO}_2 < 60 \text{ mmHg} \) not reversible to 100% oxygen may develop prolonged respiratory failure in the post-transplant period [10, 11].

In contrast, PoPH is a form of secondary pulmonary arterial hypertension occurring in only 2–8% of cirrhotic patients [15] and, as in HPS, it can also be seen in patients with non-cirrhotic portal hypertension. Presenting symptoms include dyspnea and fatigue and signs of increased workload of the right heart, such as elevated jugular venous pulse and tricuspid regurgitation. Other causes for PAH have to be ruled out and patients with PoPH require meticulous optimization of PAH-specific therapies prior to indication for LT. Treatment of PoPH includes inhaled or intravenous prostaglandins and agents such as sildenafil or bosentan, which are improved therapies prior to management of pulmonary hypertension and allow facilitating successful LT in this high-risk population. It is essential that the diagnosis of either arterial or venous pulmonary hypertension is identified and the latter may be successfully treated by addressing the volume status. Right heart catheterization is an essential component of assessment following echocardiography. Patients with PoPH have poorer survival when undergoing LT, but transplantation should be considered only in patients with mild PoPH or those responding to medical therapy with pulmonary vasodilators and MPAP < 35 mmHg [10].

In summary, pulmonary complications are important in well-defined subgroups of end-stage liver disease. These patients require meticulous assessment prior to listing and reflect high-risk patients in the peritransplant setting due to the development of right heart or weaning failure, respectively. Vice versa, deterioration of liver function and hypoxic hepatitis as a result of (right) heart failure can aggravate intrapulmonary shunting due to acutely developing HPS, an underestimated phenomenon in the general ICU population.

Author details
1 Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany. 2 Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. 3 Department of Critical Care, Kings College Hospital Foundation Trust, London, UK. 4 Department of Medicine B, University Hospital Münster, Münster, Germany.

Acknowledgements
The cartoon in the figure was provided by Dr. M. Leitner from the Center for Sepsis Care & Control, University Hospital Jena, Germany.

Compliance with ethical standards

Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.

Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 29 May 2019 Accepted: 28 July 2019 Published online: 2 August 2019

References
1. Yang P, Formanek P, Scaglione S, Afshar M (2019) Risk factors and outcomes of acute respiratory distress syndrome in critically ill patients with cirrhosis. Hepatol Res 69(3):744–745
2. O’Brien AJ, Welch CA, Singer M, Harrison DA (2012) Prevalence and outcome of cirrhosis patients admitted to UK intensive care: a comparison against dialysis-dependent chronic renal failure patients. Intensive Care Med 38(6):991–1000
3. Fuhrmann V, Whitehouse T, Wendon J (2018) The ten tips to manage critically ill patients with acute-on-chronic liver failure. Intensive Care Med 44(11):1932–1935
4. Raevens S, Geerts A, Van Steenkiste C et al (2015) Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. Liver Int 35(6):1646–1660
5. West R, Alblilos A, Trauner M et al (2017) Targeting the gut-liver axis in liver disease. J Hepatol 67(5):1084–1103
6. Fuhrmann V, Krowka M (2018) Hepatopulmonary syndrome. J Hepatol 69(3):744–745
7. Krowka MJ, Wiesner RH, Heimbach JK (2013) Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward. J Hepatol 59(2):367–374
8. Iyer VN, Swanson KL, Cartin-Ceba R, Dierkhising RA, Rosen CB, Heimbach JK, Wiesner RH, Krowka MJ (2013) Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology 57(6):2427–2435
9. Fuhrmann V, Madi C, Mueller C, Holzinger U, Kitzberger R, Funk GC, Schenk P (2006) Hepatopulmonary syndrome in patients with hypoxic hepatitis. Gastroenterology 131(1):69–75
10. Burra R, Burroughs A, Grazzioli I et al (2016) EASL clinical practice guidelines: liver transplantation. J Hepatol 64:433–485
11. Krowka MJ, Fallon MB, Kawut SM et al (2016) International Liver Transplant Society Practice Guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation 100(7):1440–1452
12. Schiffer E, Majno P, Mentha G et al (2006) Hepatopulmonary syndrome increases the postoperative mortality rate following liver transplantation: a prospective study in 90 patients. Am J Transplant 6(8):1430–1437
13. Santos J, Young P, Barijakareve I et al (2014) The successful use of inhaled nitric oxide in the management of severe hepatopulmonary syndrome after orthotopic liver transplantation. Case Rep Hepatol 2014:415109. https://doi.org/10.1155/2014/415109
14. Sharma NS, Wille KM, Dicz Guzman E (2015) Extracorporeal membrane oxygenation after liver transplantation in a patient with hepatopulmonary syndrome and an atrial septal defect. Int J Artif Organs 38(3):170–172
15. Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, Ramsay M, Davis GL (2007) The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 7(5):1258–1264